Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protara Therapeutics, Inc. (TARA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Protara is a clinical-stage biotechnology company listed on The Nasdaq Global Market under the symbol TARA, and its filings offer insight into the development of its investigational therapies TARA-002 and IV Choline Chloride, as well as its capital raising activities.
Among the key documents available are Form 8-K current reports, where Protara reports material events such as public offerings of common stock under its shelf registration statement on Form S-3, interim clinical data from the Phase 2 ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC), and interim results from the Phase 2 STARBORN-1 trial in pediatric lymphatic malformations (LMs). These filings also describe regulatory feedback from the U.S. Food and Drug Administration (FDA) on registrational trial designs and summarize safety and efficacy data disclosed in associated press releases and investor presentations.
Investors can also use this page to track financing-related disclosures, including details of underwritten public offerings, the number of shares issued, gross proceeds, and the intended use of net proceeds, which Protara states include funding the clinical development of TARA-002 and other clinical programs, as well as working capital and general corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of clinical updates, regulatory interactions, and financing transactions. Real-time updates from EDGAR mean that new Protara filings, such as additional 8-Ks, quarterly or annual reports when filed, and other registration statements, can be reviewed soon after submission.
For users interested in governance and ownership details, this page also serves as a starting point to locate information typically found in periodic and transactional filings, while AI-generated overviews can make complex regulatory language more accessible to a broader audience.
Protara Therapeutics Chief R&D Officer sells shares under trading plan. Jacqueline Zummo completed an open-market sale of 22,598 shares of Protara Therapeutics common stock at a weighted average price of $5.26 per share. After this automatic sale under a Rule 10b5-1 trading plan established on December 31, 2025, she directly holds 95,961 shares.
Protara Therapeutics, Inc. reported updated interim data from its ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ non-muscle invasive bladder cancer that is Bacillus Calmette-Guérin (BCG)-Unresponsive. The company confirmed the six-month complete response rate for the 25th BCG-Unresponsive patient, yielding an average six-month complete response rate of 68.0% in these 25 patients. This result is consistent with the previously announced six-month complete response rate of 68.2% and remains meaningfully above 41.9%. Based on this outcome, Protara determined that a condition in its April 2024 common stock purchase warrants has been satisfied, so those warrants are exercisable at $5.25 per share at any time on or prior to June 29, 2026.
Protara Therapeutics, Inc. files its annual report describing significant progress across its oncology and rare disease pipeline. The company is developing TARA‑002, an intravesical and intracystic cell therapy, for non‑muscle invasive bladder cancer (NMIBC) and pediatric lymphatic malformations (LMs), and IV Choline Chloride for patients on long‑term parenteral support.
Interim Phase 2 ADVANCED‑2 data in NMIBC show complete response rates of 65.7% in BCG‑unresponsive and 72.4% in BCG‑naïve cohorts, with most treatment‑related events Grade 1 and transient. FDA feedback supports a registrational design for a controlled BCG‑naïve trial, and the company plans to start ADVANCED‑3 in the second half of 2026.
In LMs, Phase 2 STARBORN‑1 interim results in 12 pediatric patients showed 100% clinical success among eight evaluable patients, with most achieving meaningful volume reductions after one or two doses and a favorable safety profile. For IV Choline Chloride, Protara has FDA alignment on a registrational path, Fast Track and Orphan Drug designations, and has initiated THRIVE‑3, a seamless Phase 2b/3 trial using plasma choline change as the primary endpoint.
Protara Therapeutics reported fourth quarter and full year 2025 results while highlighting progress across its late-stage pipeline. TARA-002 showed a 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer in the ADVANCED-2 trial. The company plans to complete enrollment of this registrational cohort and start the ADVANCED-3 registrational trial in BCG-naïve patients in the second half of 2026.
For rare diseases, TARA-002 in lymphatic malformations received Breakthrough Therapy and Fast Track designations, with a regulatory update expected in the first half of 2026. Interim data from the THRIVE-3 registrational trial of IV Choline Chloride in patients on long-term parenteral support are expected in the second half of 2026. Protara completed an oversubscribed $86 million public offering and ended 2025 with about $198 million in cash, cash equivalents and investments, which it expects will fund operations into 2028. Full-year 2025 net loss was $57.4 million on operating expenses of $64.5 million, driven mainly by research and development spending.
TARA reported a Form 144 notice covering proposed sales of common stock by holders, with Canaccord Genuity LLC listed as a broker. The filing lists three sales by 667, L.P. in the past three months: 02/24/2026 26,755 shares (proceeds $161,584.00), 02/25/2026 78,716 shares (proceeds $457,046.00), and 03/04/2026 35,173 shares (proceeds $220,151.00). The filing also shows broker information for 03/06/2026.
Baker Brothers Life Sciences filed a Form 144 reporting proposed sales of Common Stock of TARA. The filing lists three brokered sales: 322,039 shares on 02/24/2026 for $1,944,922; 947,479 shares on 02/25/2026 for $5,501,316; and 424,125 shares on 03/04/2026 for $2,654,641.
Protara Therapeutics is registering up to 21,686,760 shares of common stock for resale by selling stockholders. This prospectus supplement updates the May 9, 2024 prospectus and breaks the 21,686,760 shares into 9,143,380 Initial Shares, 1,700,000 Pre-Funded Warrant Shares and 10,843,380 Common Warrant Shares.
The supplement adds selling holders and updates the selling stockholder table as of March 6, 2026, including assignments of Common Warrants for up to 200,000 warrant shares to Warberg Special Situations Fund LP and 200,000 warrant shares to Warberg WF XIII LP. Beneficial ownership limits for those holders are listed at 4.99%.
667, L.P. reported sales of Common Stock for TARA. The filing shows sales of 26,755 shares on 02/24/2026 for $161,584.00 and 78,716 shares on 02/25/2026 for $457,046.00.
The transactions are listed through a broker (Canaccord Genuity LLC) on 03/04/2026.
Baker Brothers Life Sciences filed a Form 144 reporting proposed sales of Common Stock by broker. The filing lists proposed brokered transactions through Canaccord Genuity with a broker date of 03/04/2026. The record lists sales of 322,039 shares on 02/24/2026 and 947,479 shares on 02/25/2026. A line in the filing shows 53,587,260 shares with the date 03/04/2026 listed nearby.